In a filing, Akero Therapeutics Inc revealed its Officer Timothy Rolph acquired Company’s shares for reported $2.92 million on Jul 07 ’25. In the deal valued at $51.85 per share,56,250 shares were bought.
Then, Lamy Patrick sold 2,000 shares, generating $105,760 in total proceeds. Upon selling the shares at $52.88, the Senior VP, Commercial Strategy now owns 29,891 shares.
Before that, PATRICK D LAMY bought 2,000 shares. Akero Therapeutics Inc shares valued at $106,720 were divested by the Officer at a price of $53.36 per share.
BofA Securities upgraded its Akero Therapeutics Inc [AKRO] rating to a Buy from a a Neutral in a research note published on January 30, 2025; the price target was increased to $63 from $35. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in late January has reiterated a ‘”a Buy”‘ rating for it. Citigroup began covering AKRO with “Buy” recommendation on November 18, 2024.
Price Performance Review of AKRO
On Monday, Akero Therapeutics Inc [NASDAQ:AKRO] saw its stock fall -0.48% to $51.52. Over the last five days, the stock has lost -8.31%. Akero Therapeutics Inc shares have risen nearly 130.21% since the year began. Nevertheless, the stocks have risen 85.19% over the past one year. While a 52-week high of $58.40 was reached on 01/27/25, a 52-week low of $21.02 was recorded on 01/14/25.
Levels Of Support And Resistance For AKRO Stock
The 24-hour chart illustrates a support level at 50.48, which if violated will result in even more drops to 49.45. On the upside, there is a resistance level at 52.64. A further resistance level may holdings at 53.77.
How much short interest is there in Akero Therapeutics Inc?
A steep rise in short interest was recorded in Akero Therapeutics Inc stocks on 2025-06-13, growing by 1.45 million shares to a total of 7.75 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.3 million shares. There was a rise of 18.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $69 price target.
